Human Trials

AstraZeneca’s Imfinzi fails to improve OS in Mystic lung cancer trial

AstraZeneca’s Imfinzi (durvalumab) monotherapy and the combination of Imfinzi with remelimumab have failed to improve overall survival (OS) rate in phase III Mystic lung cancer trial.

Seattle Genetics begins blood cancer trial with SEA-BCMA

Seattle Genetics has dosed the d first patient in a phase 1 clinical trial evaluating the safety and tolerability of SEA-BCMA for patients with relapsed or refractory multiple myeloma (MM).

Merck’s Keytruda improves overall survival in phase 3 esophageal cancer trial

Merck has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) significantly improved overall survival (OS) rate in the phase 3 Keynote-181 esophageal cancer trial.

AbbVie’s Mavyret shows high virologic cure rates in HCV study

AbbVie’s Mavyret (glecaprevir/pibrentasvir) has showed high virologic cure rates in treatment-naïve patients with compensated cirrhosis in the phase 3b Expedition-8 study.

Gilead’s GS-9674 shows positive action in primary sclerosing cholangitis

Gilead Sciences announced that its GS-9674 has showed significant improvements in liver biochemistry and markers of cholestasis in patients with primary sclerosing cholangitis (PSC) in a phase 2 trial.

Visterra begins phase 1 clinical study of monoclonal antibody VIS649

Clinical stage biotechnology firm Visterra has commenced a phase 1 clinical study of VIS649 in healthy volunteers.

Glenmark plans to launch phase 1 trial in solid tumors for GBR 1342

Glenmark Pharmaceuticals has announced plans to launch a phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342.

Genkyotex’s liver disease drug GKT831 succeeds in phase 2 trial

Genkyotex’s NOX1/4 inhibitor GKT831 has succeeded in a phase 2 trial in primary biliary cholangitis (PBC), a type of liver disease, by meeting both primary and secondary interim efficacy endpoints.

BMS, Infinity to assess Opdivo-IPI-549 combo in urothelial cancer

A clinical trial collaboration has been formed to assess Bristol-Myers Squibb's (BMS) Opdivo in combination with Infinity Pharmaceuticals' IPI-549 in patients with advanced urothelial cancer.